Multiple endocrine neoplasia type 2

被引:49
作者
Gertner M.E. [1 ]
Kebebew E. [1 ]
机构
[1] Department of Surgery, Univ. of California San Francisco, San Francisco, CA 94115
关键词
Medullary Thyroid Carcinoma; Laparoscopic Adrenalectomy; Medullary Thyroid Cancer; Bilateral Neck Exploration; Total Parathyroidectomy;
D O I
10.1007/s11864-004-0022-6
中图分类号
学科分类号
摘要
Multiple endocrine neoplasia type 2 (MEN-2) is a hereditary syndrome that is transmitted in an autosomal dominant pattern. MEN-2A, MEN-2B, and familial medullary thyroid cancer (MTC) comprise the MEN-2 syndrome. A germline mutation in the RET proto-oncogene is responsible for the MEN-2 syndrome. Recent data indicate that in 99% of MEN-2 cases, a germline RET mutation can be identified by genetic testing. The phenotypic variation of MEN-2 is diverse and partly related to the codon and specific point mutation in the RET proto-oncogene. There are increasing data on the genotype-phenotype correlations in patients with MEN-2 and this information should be used for screening at-risk patients and treatment of RET mutation carriers. All patients (especially if young) with MTC or bilateral pheochromocytoma should have a careful family history taken and genetic screening for RET germline mutations. Patients who are RET germline mutation carriers but without clinical or biochemical evidence of MTC should have a prophylactic total thyroidectomy. The optimal age of thyroidectomy should be based on the RET genotype (eg, high-risk mutations [codons 634, 883, 918, and 922] within the first year of life, intermediate-risk mutations [codons 611, 618, and 620] by 5 years of age, and low-risk mutations [codons 609, 630, 768, 790, 791, 804, and 891] by 10 years of age). Patients who are diagnosed with clinical or biochemical evidence of MTC should have a total or a near total thyroidectomy and at least a central neck lymph node dissection. Patients who have pheochromocytoma and a unilateral adrenal tumor on a localizing study should have a unilateral laparoscopic adrenalectomy after preoperative α-blockade. However, patients with bilateral adrenal tumors on localizing studies should have bilateral laparoscopic adrenalectomy. A cortical-sparing (subtotal) adrenalectomy may be considered, if technically feasible, to avoid long-term steroid dependence and to reduce the risk of Addisonian crisis. Patients with biochemical evidence of primary hyperparathyroidism should have a bilateral neck exploration and total parathyroidectomy and autotransplantation (30-60 mg of the most normal parathyroid tissue) to the nondominant forearm if asymmetric parathyroid hyperplasia is present. Rarely, patients may have only single-gland disease and excision may be performed if the other parathyroid glands are not found with biopsy to be hyperplastic. All unresected parathyroid glands should be marked with a clip because patients with MEN-2A have a high risk of persistent and recurrent primary hyperparathyroidism. Patients with familial MTC may have not manifested the other features of MEN-2A, thus these patients should have continued follow-up for pheochromocytoma and primary hyperparathyroidism. Copyright © 2004 by Current Science Inc.
引用
收藏
页码:315 / 325
页数:10
相关论文
共 43 条
[1]  
Brandi M.L., Gagel R.F., Angeli A., Et al., Guidelines for diagnosis and therapy of MEN type 1 and type 2, J. Clin. Endocrinol. Metab., 86, pp. 5658-5671, (2001)
[2]  
Eng C., Clayton D., Schuffenecker I., Et al., The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2 International RET mutation consortium analysis, JAMA, 276, pp. 1575-1579, (1996)
[3]  
Nunziata V., Giannattasio R., Di Giovanni G., Et al., Hereditary localized pruritus in affected members of a kindred with multiple endocrine neoplasia type 2A (Sipple's syndrome), Clin. Endocrinol. (Oxf), 30, pp. 57-63, (1989)
[4]  
Verdy M., Weber A.M., Roy C.C., Et al., Hirschsprung's disease in a family with multiple endocrine neoplasia type 2, J. Pediatr. Gastroenterol. Nutr., 1, pp. 603-607, (1982)
[5]  
Gagel R.F., Tashjian Jr. A.H., Cummings T., Et al., The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a: An 18-year experience, N. Engl. J. Med., 318, pp. 478-484, (1988)
[6]  
Kebebew E., Ituarte P.H., Siperstein A.E., Et al., Medullary thyroid carcinoma: Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems, Cancer, 88, pp. 1139-1148, (2000)
[7]  
Brandi M., Gagel R., Angeli A., Bilezikian J., Guidelines for diagnosis and therapy of MEN type 1 and type 2, J. Clin. Endocrinol. Metab., 86, pp. 5658-5671, (2001)
[8]  
Wells Jr. S.A., Chi D.D., Toshima K., Et al., Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A, Ann. Surg., 220, pp. 237-247, (1994)
[9]  
Dralle H., Gimm O., Simon D., Et al., Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience, World J. Surg., 22, pp. 744-750, (1998)
[10]  
Machens A., Niccoli-Sire P., Hoegel J., Et al., Early malignant progression of hereditary medullary thyroid cancer, N. Engl. J. Med., 349, pp. 1517-1525, (2003)